TY - JOUR
T1 - What Do We Really Know About the Effect of Prolonged Heart Rhythm Monitoring After Stroke?
AU - Ihle-Hansen, Håkon
AU - Hagberg, Guri
AU - Ihle-Hansen, Hege
AU - Sandset, Else Chartlotte
AU - Andrade, Jason G
AU - Mandrola, John
AU - Diederichsen, Søren Zöga
PY - 2024/4
Y1 - 2024/4
N2 - The bulk of the current knowledge on atrial fibrillation (AF)-associated stroke risk and benefit of oral anticoagulation derives from studies on patients with clinically diagnosed AF. Subclinical AF (SCAF), defined as AF discovered during the interrogation of prolonged heart monitoring, is often asymptomatic and short-lasting, is associated with increased stroke risk compared with sinus rhythm, and may progress to clinical AF. Despite the extensive screening for and treatment of SCAF, especially in secondary stroke prevention, the net benefit of this practice is not established. Recent studies of SCAF have provided new insights: (1) SCAF is extremely common and may sometimes indicate physiological findings, (2) the stroke risk associated with SCAF is lower than that of clinically detected AF, and (3) any benefit on stroke risk may be countered by increased bleeding risk (no net benefit). How should we interpret the latest knowledge in the setting of poststroke AF screening and prevention?
AB - The bulk of the current knowledge on atrial fibrillation (AF)-associated stroke risk and benefit of oral anticoagulation derives from studies on patients with clinically diagnosed AF. Subclinical AF (SCAF), defined as AF discovered during the interrogation of prolonged heart monitoring, is often asymptomatic and short-lasting, is associated with increased stroke risk compared with sinus rhythm, and may progress to clinical AF. Despite the extensive screening for and treatment of SCAF, especially in secondary stroke prevention, the net benefit of this practice is not established. Recent studies of SCAF have provided new insights: (1) SCAF is extremely common and may sometimes indicate physiological findings, (2) the stroke risk associated with SCAF is lower than that of clinically detected AF, and (3) any benefit on stroke risk may be countered by increased bleeding risk (no net benefit). How should we interpret the latest knowledge in the setting of poststroke AF screening and prevention?
KW - Atrial Fibrillation/complications
KW - Humans
KW - Risk Factors
KW - Stroke/diagnosis
KW - diagnostic screening programs
KW - atrial fibrillation
KW - electrocardiography, ambulatory
KW - ischemic stroke
UR - http://www.scopus.com/inward/record.url?scp=85188732387&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.123.045843
DO - 10.1161/STROKEAHA.123.045843
M3 - Comment/debate
C2 - 38456295
SN - 0039-2499
VL - 55
SP - 1136
EP - 1140
JO - Stroke
JF - Stroke
IS - 4
ER -